Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S. Falchook, Leslie A. Fecher, Stephen A. Szabo et al.|The Lancet Oncology|2012Cited by 541
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumorsJean‐Charles Soria, Michael Millward, Hui Gan et al.|Annals of Oncology|2016Cited by 145
610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent MesotheliomaJean‐Charles Soria, M.J. Millward, Ruth Plummer et al.|European Journal of Cancer|2012Cited by 8
613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid TumorsHui Gan, M.J. Millward, Noelia Nebot et al.|European Journal of Cancer|2012Cited by 3